MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$3,455,574
Unit: Dollar
Positive Cash Flow Breakdown
Net proceeds from issuance of sh...
Stock-based compensation expense
Other non-cash items
Others
Negative Cash Flow Breakdown
Net loss
Accounts payable and other curre...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-4,675,571
-5,608,732
-4,537,581
-5,284,373
Depreciation and amortization
27,170
21,303
28,241
22,817
Stock-based compensation expense
566,050
403,509
401,667
460,005
Other non-cash items
-99,914
-230,462
-11,194
-10,864
Prepaid expenses and other current assets
215,108
278,213
-304,426
-866,395
Long-term deposits and other noncurrent assets
-10,766
913
-533
-541
Accounts payable and other current liabilities
-485,104
531,767
-785,258
-949,139
Defined benefit pension plan
-30,567
-26,710
-26,866
-103,702
Deferred grant income
22,445
-
-14,843
-18,239
Total changes in operating assets and liabilities
697,568
-225,931
522,008
135,749
Cash used in operating activities
-4,680,005
-4,727,527
-4,618,487
-4,926,436
Net proceeds from issuance of shares in atm offering (note 13)
1,391,359
427,783
13,149,139
0
Net proceeds from issuance of shares in public offering (note 14)
-
-
0
7,411,554
Net proceeds from the exercise of warrants (note 13)
0
2,063
3,176,807
41,745
Net proceeds from the exercise of stock options (note 15)
-
-
250,260
-
Payments of offering costs (note 14)
-
-
0
395,478
Payments of current portion of long-term debt (note 11)
25,297
25,525
25,025
24,996
Cash provided by financing activities
1,366,062
404,321
16,551,181
7,032,825
Effect of exchange rate changes
-141,631
24,589
97,760
6,667
Net decrease in cash, cash equivalents and restricted cash
-3,455,574
-4,298,617
12,030,454
2,113,056
Cash, cash equivalents and restricted cash at beginning of period
16,575,307
20,873,924
8,843,470
10,417,558
Cash, cash equivalents and restricted cash at end of period
13,119,733
16,575,307
20,873,924
8,843,470
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net proceeds from
issuance of shares in atm...
$1,391,359
(-71.66%↓ Y/Y)
Cash provided by
financing activities
$1,366,062
(-71.91%↓ Y/Y)
Canceled cashflow
$25,297
Net decrease in
cash, cash...
-$3,455,574
(6.28%↑ Y/Y)
Canceled cashflow
$1,366,062
Stock-based compensation
expense
$566,050
(-39.88%↓ Y/Y)
Other non-cash items
-$99,914
(87.24%↑ Y/Y)
Depreciation and
amortization
$27,170
(-36.80%↓ Y/Y)
Payments of current
portion of long-term...
$25,297
(-45.57%↓ Y/Y)
Cash used in
operating activities
-$4,680,005
(47.54%↑ Y/Y)
Canceled cashflow
$693,134
Effect of exchange rate
changes
-$141,631
(-138.32%↓ Y/Y)
Deferred grant income
$22,445
(107.61%↑ Y/Y)
Long-term deposits and
other noncurrent...
-$10,766
(-505.51%↓ Y/Y)
Net loss
-$4,675,571
(54.78%↑ Y/Y)
Total changes in
operating assets and...
$697,568
(100.02%↑ Y/Y)
Canceled cashflow
$33,211
Accounts payable and
other current...
-$485,104
(-138.32%↓ Y/Y)
Prepaid expenses and
other current assets
$215,108
(-82.83%↓ Y/Y)
Defined benefit pension
plan
-$30,567
(55.31%↑ Y/Y)
Buy us a coffee
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX)